ZyVersa Therapeutics Inc is a clinical stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop and commercialize first-in-class prescription drugs. The company's focus is on restoring health and improving quality of life for patients with high unmet medi... ZyVersa Therapeutics Inc is a clinical stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop and commercialize first-in-class prescription drugs. The company's focus is on restoring health and improving quality of life for patients with high unmet medical needs, with emphasis on inflammatory and renal diseases. Show more
Strokes affect 795,000 people annually in the US. Obesity, a top risk factor for strokes, is associated with around one out of five strokes.Cardiac complications following a stroke are a leading...
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor...
KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesity, Metabolic &...
During obesity, inflammasome-driven inflammation results in significant loss of pancreatic islet beta cell mass, severely impairing the insulin secreting capacity of the remaining beta...
Obesity, due to its associated chronic, systemic inflammation, increases the risk for metabolic diseases, atherosclerosis, various malignant tumors, and numerous immune-mediated disorders.With...
Recent evidence links obesity-driven inflammation to diminished brain health and neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseasesThe newly published data show that obesity...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0401 | 3.93137254902 | 1.02 | 1.15 | 0.9801 | 73223 | 1.03164497 | CS |
4 | -0.1899 | -15.192 | 1.25 | 1.35 | 0.9801 | 270320 | 1.14154527 | CS |
12 | -1.1699 | -52.4618834081 | 2.23 | 3.37 | 0.9801 | 1317729 | 2.37506441 | CS |
26 | -3.3699 | -76.0699774266 | 4.43 | 6.3 | 0.9801 | 685472 | 2.5622412 | CS |
52 | -7.6389 | -87.8135417864 | 8.699 | 25 | 0.9801 | 1149251 | 7.25284573 | CS |
156 | -4898.9399 | -99.9783653061 | 4900 | 5232.5 | 0.9801 | 2014669 | 80.12786157 | CS |
260 | -4898.9399 | -99.9783653061 | 4900 | 5232.5 | 0.9801 | 2014669 | 80.12786157 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales